Valley fever
FDA Clears DxNA's Valley Fever Molecular Test
The test runs on the GeneSTAT system, and has demonstrated 100 percent sensitivity, 99.6 percent specificity, and 100 percent reproducibility.
DxNA Files for FDA Clearance of MDx System, Valley Fever Assay
The firm's real-time PCR-based GeneStat system was developed leveraging IP licensed exclusively from the Translational Genomics Research Institute.
DxNA Receives $2.5M Equity Investment
NEW YORK (GenomeWeb News) – Molecular diagnostics company DxNA has received a $2.5M equity investment from an unnamed individual investor.
ASU's Biodesign Institute Wins $30M DoD Contract for Immunosignature-Based Pathogen Detection Chip
Premium
This story originally ran on April 26.
The company is developing and validating assays for difficult-to-treat and drug-resistant infectious diseases based primarily on targets, biomarkers, and PCR primers developed at the Translational Genomics Research Institute and Northern Arizona University.